Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / VCAN

VCAN

Basics

Aliases:
This biomarker is also known as:
  • Chondroitin sulfate proteoglycan core protein 2,
  • versican proteoglycan,
  • GHAP,
  • Large fibroblast proteoglycan,
  • chondroitin sulfate proteoglycan 2,
  • PG-M,
  • versican,
  • Glial hyaluronate-binding protein,
  • ERVR,
  • WGN,
  • WGN1,
  • versican core protein,
  • CSPG2,

View in BioMuta

Description…

VCAN, or CSPG2, a large chondroitin sulfate proteoglycan, is a major component of the extracellular matrix. This secreted protein is involved in cell adhesion, proliferation, migration and angiogenesis and plays a central role in tissue morphogenesis and maintenance. It is may play a role in intercellular signaling. Mutations in the CSPG2 gene are the cause of Wagner syndrome type 1. Multiple transcript variants encoding different isoforms have been found for this gene.

Attributes

QA State: Curated
Type: Protein
Short Name:
HGNC Name: VCAN

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Ovary

Attributes

Phase: Three
QA State: Under Review

Overview

VCAN (CSPG2) was shown to localize to vascular-like structures in ovarian cancer but not in normal ovaries.

Performance Comment

VCAN, or CSPG2, was one of 13 genes out of 50 selected for further validation in PMID:21617380. Average expression of VCAN was significantly higher in epithelial ovarian cancer tumors than any other normal tissue tested.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Announcement 11/20/2014

New Round of EDRN FOAs

The RFAs for EDRN have been released:
- Biomarker Developmental Laboratories (U01),
- Clinical Validation Centers (U01),
- Biomarker Reference Laboratories (U24),
- Data Management and Coordinating Center (U24).

EDRN Renewal flyer NOTE-New receipt deadline for applications submitted for all EDRN FOAs is January 20, 2015, by 5:00 PM local time of applicant organization.

There will be a Pre-Application webinar to discuss each of the four individual EDRN FOAs on Tuesday, December 2nd, 2014, from 1pm-5pm (Eastern). Potential applicants interested in participating in the webinar should send a message to Dr. Sharmistha Ghosh (ghoshjanjigias@mail.nih.gov) no later than 5:00 p.m. (EST) November 21, 2014. Please mention the FOA of interest in the subject line.

Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.